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Summary We have studied the response of human mesothelioma xenografts in nude mice to Photofrins-
sensitised photodynamic therapy with 514 nm light. Delays in tumour regrowth following four different 514 nm
irradiation regimens were compared with results obtained with the more commonly used 630 nm light. One of
these 514 nm regimens, which consisted of 1 h of irradiation at an incident fluence rate of 20 mW cm-2 and a
second hour at a fluence rate of 28 mW cm 2, produced tumour volume doubling times that were statistically
indistinguishable from results that were observed when tumours were irradiated for 2 h with 630 nm light at an
incident fluence rate of 50 mW cm-2. The three other 514 nm light protocols tested were found to be less
effective than the 630 nm regimen. The 514 nm treatment protocols were devised on the basis of attempts to
equate the photodynamic dose and the dose rate at these two wavelengths, with photodynamic dose defined as
the number of photons absorbed by the sensitiser. Photosensitiser extinction coefficients, photon energies and
tissue optical properties were considered in these attempts. Our results indicate that, under certain conditions,
photodynamic therapy performed with 514 nm light can provide tumour control that is similar to that achieved
with 630 nm, with potential for diminished normal tissue damage.
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Photodynamic therapy (PDT) is gaining a measure of
increased clinical acceptance as an intervention in several
malignant and non-malignant conditions (Marcus, 1992;
Furuse et al., 1993). The recent Canadian and Dutch limited
approvals of the porphyrin photosensitiser Photofring's are
evidence of this trend. While a major emphasis in PDT
research has been and continues to be the development of
new photosensitisers that overcome some of Photofrins'g
inherent limitations (Gomer, 1991), it is likely that
Photofring will remain in widespread use for some time. It
is therefore important to continue efforts directed at the
optimisation of Photofrin'-sensitised PDT.
Although Photofrin' absorbs light throughout the visible
spectrum, typical treatment regimens include irradiation at or
near 630 nm, which corresponds to the longest wavelength
absorption band of this photosensitiser. This is done in order
to take advantage of increased optical penetration in tissue.
However, there are clinically relevant situations in which this
deeper optical penetration is neither necessary nor desirable.
In treating relatively thin lesions that reside at the surface of
otherwise healthy tissue, the more rapid attenuation of
shorter wavelength light offers the possible advantage of
improving the therapeutic ratio. This consideration is of high
importance in the case of the oesophagus, for example, where
perforation of the wall is potentially catastrophic.
Haematoporphyrin derivative (HpD)- and Photofrinm-
sensitised PDT have been performed by other investigators
using the 514 nm output of the argon-ion laser in preclinical
(Bellnier et al., 1985; van Gemert et al., 1985; Tochner et al.,
1986; Nseyo et al., 1993) and clinical (DeLaney et al., 1993)
settings. These studies have demonstrated the potential of
514 nm irradiation to induce tumour necrosis at depths of 2-
3 mm. The purpose of the present study was to extend this
earlier work and to identify criteria for a somewhat more
quantitative dosimetry at this treatment wavelength. Our goal
was to establish treatment conditions at 514 nm that
produced long-term delays in the regrowth of human
mesothelioma xenografts that were similar to those that
had been previously reported using 630 nm irradiation
(Gibson et al., 1994). Effective criteria for comparing 514
and 630 nm dosimetry must include the difference in the
photosensitiser's extinction coefficients, the difference in
photon energies and at least a qualitative determination of
the difference in tissue optical properties at these wavelengths.
Photofrin®'s extinction coefficient at 514 nm is approximately
3-fold greater than it is at 630 nm, and the ratio of photon
energies at these wavelengths (514:630 nm) is 1.22. These
factors combine such that, in the absence of tissue optical
property differences, equivalent rates of photon absorption
are achieved when the energy fluence rate at 514 nm is
reduced 2.5-fold relative to that at 630 nm. Increased
attenuation of light at 514 nm, however, ensures that the
rate of photon absorption cannot be matched at all depths in
the tumour simultaneously. In an attempt to account for all
three of these factors, we have designed and tested four
separate 514 nm irradiation schemes. Tumour responses to
these protocols were compared with results obtained using
630 nm light.
Materials and methods
Chemicals
Photofrin9 was a generous gift from Quadra Logic
Technologies (Vancouver, British Columbia, Canada). It
was received as a lyophilised powder, solubilised in 5%
dextrose to a final concentration of 2.5 mg ml-', divided into
0.5 ml aliquots and stored at -70°C until thawed
immediately before use.
Animals and tumours
Mesothelioma tumours were initially propagated by sub-
cutaneous injection of a 0.2 ml suspension of S x 105 H-
MESO-1 cells (Mason Research Labs, Worcester, MA, USA)
into the flanks of athymic nude mice (Ncr-nu). Tumours grew
to a diameter of 10 mm within 30 days of cell implantation.
Subsequently, tumours were transplanted by incisional
transplantation of 1 mm3 sections into the flanks of
halothane-anaesthetised nude mice. Serial transplantations
were limited to five passages using tissue that had been
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frozen from passage 1 or 2. Tumour samples were
occasionally removed from mice for histological examination
by a veterinarian pathologist and were confirmed to be of
mesothelioma origin. Tumours typically achieved suitable
treatment size (5-6 mm in diameter, 0.1-0.17 cm3) within
7- 12 days of implantation. All animals were cared for under
guidelines established by the University Committee on
Animal Resources at the University of Rochester.
PDT treatment conditions
Tumour-bearing mice were administered Photofring i.p. at a
dose of 5 mg kg-'. At 24 h after photosensitiser administra-
tion, animals were anaesthetised with 75 mg kg-1 ketamine
hydrochloride (Parke Davis, Morris Plaines, NJ, USA) and
6 mg kg-1 xylazene (Miles Inc., Shawnee Mission, KS, USA),
which provides effective chemical restraint for approximately
1 h. Injections of half the initial volume of anaesthesia were
administered thereafter as needed. Tumours were irradiated
with the 514 nm output of an air-cooled argon-ion laser (Ion
Laser Technologies, Salt Lake City, UT, USA). The laser
light was lens-coupled to a 400 gm internal diameter optical
fibre, which was positioned above the tumour to produce a
circular 1 cm2 light field at the treatment site. Irradiation was
delivered continuously for 2 h at a constant incident energy
fluence rate ofeither 20 (n = 19) or 28 (n = 11) mW cm-2 or at
20 mW cm-2 for 1 h followed immediately by irradiation at
either 28 (n= 11) or 40 (n= 10) mW cm-2 for an additional
1 h. The fluence rates of 20 and 28 mW cm-2 were selected in
initial attempts to match the rate of sensitiser photon
absorption with the rate that occurs during irradiation at
50 mW cm-2 using 630 nm light. The 514 nm intensities were
based on estimated ratios of absorbance (514:630) for
Photofring of 3 and 2.18 respectively. The latter absorbance
ratio was reported by Bellnier et al. (1985) and was derived
from measurements of MBT-2 tumour tissue. The variable
fluence rate, 'stepped' protocols were introduced in an effort
to approximately match the rate of photon absorption in
deeper regions of the tumour as the irradiation progressed.
Tumour response was measured as the number of days
required for the tumour to double its initial volume. The
tumour volumes were computed from two orthogonal
transdermal calliper measurements and assuming a cylind-
rical tumour geometry (Gibson et al., 1990a). Results of the
514 nm PDT treatment protocols were compared with data
obtained using 630 nm irradiation (50 mW cm-2, 2 h), a
subset of which was previously published (Gibson et al.,
1994).
Statistical analysis
The tumour volume doubling times that resulted from the
various treatment protocols were compared using the log-
rank test. This test is commonly used to analyse time-to-event
(e.g. survival) data in clinical research (Dawson-Saunders and
Trapp, 1994). It properly accounts for those animals whose
tumours had not reached the specified endpoint (volume
doubling) at the end of an observation period. Exact, small-
sample P-values for the tests were computed using the
program Stat-Xact (Cytel Software, Cambridge, MA, USA).
Comparisons yielding two-sided P-values less than 0.05 were
considered to represent statistically significant differences.
Median doubling times and their 95% confidence intervals
were calculated by the method of Brookmeyer and Crowley
(1982).
Results
Tumour responses to the various 514 and 630 nm irradiation
protocols are summarised in Table I. All of the treatment
regimens produced delays in tumour volume doubling times
that were highly significant with respect to controls
(P<0.001).
Among the green (514 nm) light protocols, the stepped
irradiation scheme using an incident intensity of
20 mW cm-2 for the first hour followed by 28 mW cm-2
for the second hour (the 20:28 protocol; Table I, group 5)
produced the longest delay in median tumour volume
doubling time. This median doubling time of 72 days may
be compared with the doubling times of 18 days
(20 mW cm-2; Table I, group 3), 25 days (28 mW cm
Table I, group 4) and 20 days (20:40 protocol; Table I, group
6) obtained with the other 514 nm irradiation schemes.
Statistical analysis based on the log-rank test provides a
comparison that incorporates all of the treated animals,
including those whose tumours did not recur during
observation. On the basis of this analysis, the 20:28
irradiation schedule was significantly more effective than
either the 28 mW cm-2 or the 20:40 treatment, with P-values
of 0.01 for both of these comparisons. The mesothelioma
tumour response to the 20:28 irradiation was not, however,
found to be significantly different than that observed for the
20 mW cm-2 treatment, although the median doubling times
for these two groups differed considerably (72 vs 18 days).
This apparent discrepancy is the result of several long-term
cures among the 20 mW cm-2 group.
Comparisons between the various 514 nm treatment
groups and the benchmark 630 nm group revealed that the
mesothelioma response to the red light, 50 mW cm-2
treatment was significantly better than it was to three of
the four green light protocols. Tumour regrowth following
630 nm irradiation was delayed significantly longer than it
was in response to continuous 514 nm irradiation at
20 mW cm-2 or 28 mW cm-2 and following the stepped
20:40 irradiation. In each of these three comparisons, the P-
values returned by the log-rank analysis were <0.006. In
contrast, the response of the mesothelioma xenografts to the
20:28 irradiation could not be distinguished statistically from
that of the 630 nm treatment group. The various statistical
intercomparisons are presented in Table II.
Table I Response of mesothelioma xenografts to PDT
Irradiation
Wavelength Fluenece rate Days to double initial volume Number of tumours Median doubling
Group A(nm) (mWcm-2) (number of mice) doubling out of total timea (days)
1 0 1(4), 2(3), 3(7), 4(3), 5(1), 7(3) 21/21 3 (2-4)b
2 630 50 26c, 28, 29, 33C, 37C, 38C, 40c (3), 4/16 100 (54-oo)
44C 54, 61', 69c, 100, 151c, 158c
3 514 20 7, 8, 9, 12(2), 14, 16(2), 17, 18, 20, 14/19 18 (14-70)
26, 48, 70, 88c, 103c, 140c, 143c, 182C
4 514 28 13, 14, 18, 21(2), 25, 28, 29, 36, 50, 97 11/11 25 (18-36)
5 514 20/28d 16, 20, 27, 31, 55, 72, 100, 203c, 7/11 72 (27-oo)
268c, 376c, 382c
6 514 20/40e 10, 16(2), 17, 20, 35, 37, 38, 40, 57 10/10 20 (16-38)
aMedian number of days for tumours to double their initial volume. bNumbers in parentheses represent the 95% confidence intervals for the
medians. cNumber of post-treatment observation days for tumours that did not double in volume. Irradiation delivered at 20 mW cm-2 for 1 h
followed by 1 h irradiation period at 28 mW cm-2. eSecond hour ofirradiation was performed at 40 mW cm-2 following 1 h at 20 mW cm-2.Photodynamic therapy with 514 nm light
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Table II Statistical analysis of tumour response to PDT
Group P-values
1 vs 2-6 <0.001
2 vs 3 0.006
4 <0.001
5 0.297
6 <0.001
3 vs 4 0.576
5 0.161
6 0.416
4 vs 5 0.012
6 0.916
5 vs 6 0.015
Discussion
We have studied the long-term responses of human
mesothelioma xenografts in nude mice to Photofrin®-
sensitised PDT using 514 nm laser irradiation. Responses to
four separate irradiation regimens were determined. While all
of these irradiation protocols produced delays in tumour
regrowth that were significant relative to untreated lesions,
only the stepped 20:28 regimen resulted in responses that
were statistically indistinguishable from those obtained using
630 nm light administered for 2 h at an incident fluence rate
of 50 mW cm-2 (group 2). Other investigators have examined
Photofring or HpD-sensitised PDT with 514 nm irradiation
and have demonstrated efficacy. Bellnier et al. (1985) reported
that the short-term (7 day) response of a subcutaneous,
chemically induced bladder cancer model in mice was
equivalent when tumours were irradiated with 514 and
630 nm light (80 mW cm-2, 144 J cm-2). Tumours in that
study were reported to have been less than or equal to
2.5 mm in thickness. Van Gemert et al. (1985) demonstrated
that green (514 nm) light was more efficient than red
(630 nm) light in inducing tumour necrosis to depths up to
approximately 1.2 mm. To the best of our knowledge, our
present study represents the first attempt to compare green vs
red light PDT irradiation using long-term tumour regrowth
as the experimental end point.
Previously published work from our laboratory and from
other laboratories has shown the importance of the incident
irradiation fluence rate in optimising therapeutic outcome in
certain rodent tumour models (Gibson et al., 1990b; Cincotta
et al., 1994) and in the mesothelioma xenograft (Gibson et
al., 1994). In these systems, a given optical energy density
produced significantly longer tumour volume doubling times
when the fluence rate was reduced over the range 200-
50 mW cm-2. In the initial design of our 514 nm treatment
protocols, we therefore sought to equate the rate at which
photons were absorbed by the photosensitiser with the
corresponding rate at 630 nm. It is important to emphasise
that matching the rate of photon absorption is quite different
from matching the incident energy fluence rate. Since
significant long-term tumour response in the Photofrin®-
sensitised mesothelioma xenografts had been accomplished
with 630 nm irradiation using a treatment fluence rate of
50 mW cm-2 and a total fluence of 360 J cm-2, we
established these as the basis for our comparison. Matching
the rate of photon absorption for two treatment wavelengths
requires correction for the photosensitiser extinction coeffi-
cients and for the difference in photon energies at the two
wavelengths. The Photofrin' extinction is approximately
three times greater at 514 nm than it is at 630 nm (Moan
and Sommer, 1984; Bellnier et al., 1985), and the ratio of
photon energies (514:630) is approximately 1.22, which means
that at a given energy fluence rate, the photon fluence rate at
514 nm is reduced with respect to that at 630 nm by this
factor. These two considerations combine such that, in order
to equate the rates of photon absorption by Photofring, the
energy fluence rate at 514 nm must be reduced by a factor of
2.5 relative to 630 nm. Thus, a 50 mW cm-2 incident fluence
rate at 630 nm is approximately equivalent to 20 mW cm-2
at 514 nm in terms of the rate of photon absorption, and this
was the basis for selection of 20 mW cm-2 as one of our
514 nm treatment intensities. From measurements performed
using thin sections of HpD-sensitised murine bladder tumour
tissue, Bellnier et al. (1985) reported the ratio of extinction
coefficients (514:630) to be 2.18. This value was the basis for
the 28 mW cm-2 514 nm irradiation protocol.
However, these considerations do not take into account
the increased optical attenuation of the shorter wavelength
light in tissue. Although we do not have quantitative optical
absorption and scattering coefficients for this tumour at these
wavelengths, it is certain that the 514 nm light is more
rapidly attenuated. Thus, although it is possible to match
rates of photon absorption for two wavelengths at a single
depth in the tumour, for example, at the surface, the more
rapid attenuation of the green light creates a situation in
which it is not possible to match rates of absorption
simultaneously throughout the tumour volume. If one
chooses to increase the incident intensity at 514 nm in order
to attempt to match the fluence rate at some depth within the
tumour, then the tissue that is more proximal to the incident
beam will be subjected to a fluence rate that is higher than
optimal, and the therapeutic efficacy will be compromised.
This predicament suggests a new strategy that increases or
steps the fluence rate as the PDT irradiation proceeds.
Initially, a low fluence rate (,<20 mW cm-2) should be used
to optimally treat the most superficial region. As the
treatment continues and a threshold dose is achieved near
the surface, the incident fluence rate should be increased to
effectively administer photodynamic dose to the deeper
tumour regions. It was this rationale that led us to
implement the stepped 20:28 and 20:40 irradiation regimens.
Statistical analysis of the mesothelioma responses to these
stepped regimens shows that irradiation with 40 mW cm-2
during the second half of the treatment is significantly less
effective than with 28 mW cm-2. This finding is consistent
with previously reported results obtained with Photofring-
sensitised mesothelioma xenografts and 630 nm irradiation,
where relatively lower fluence rates were found to be more
effective (Gibson et al., 1994). Our interpretation of these
data is that rapid photochemical oxygen consumption at
higher irradiation fluence rates creates regions of transient
hypoxia within which singlet oxygen formation is reduced
(Foster et al., 1991). We are encouraged by the similar
responses of the mesothelioma xenografts to the 20:28 green
and the 50 mW cm-2 red light protocols, however, our
approach to the design of the stepped irradiation schemes at
the shorter wavelength was somewhat empirical, and more
work needs to be done in order to develop treatment
strategies that are based on real knowledge of tumour
optical properties in vivo.
Attention to the factors governing green light dosimetry
for PDT underscores an elementary aspect of photochemistry
that has been overlooked in some published experimental
designs. Photodynamic dose derives from photons that are
absorbed by the photosensitiser and not simply from the total
optical energy density deposited in a tissue volume. This can
be readily seen if one compares these quantities for the cases
that we have treated in this report. Assuming that the similar
therapeutic outcomes in response to the 50 mW cm-2 red
light and 20:28 green light treatments are the result of
approximately equal photodynamic doses in the mesothelio-
ma xenografts, it follows that these treatments produced
similar spatial distributions of absorbed photons. However,
the optical energy densities deposited in the tissue were
appreciably different in these two cases. The 2 h, 630 nm
irradiation resulted in a total fluence of 360 J cm-2, whereas
the 20:28, 514 nm irradiation of the same duration resulted in
a fluence of only 173 J cm-2. Failure to take these factors
into account may lead to study designs that result in overly
pessimistic appraisals ofthe potential ofgreen light PDT with
Photofrin®. Nseyo et al. (1993), for example, examined the
response of normal canine bladders to 514 and 630 nmx Phe_ tbenvySIh~~~w 514 - g Phmnodynu,dc Uusry if 1 t
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Photofrinx-sensitised PDT and concluded that green light
was more toxic to the normal bladder. Their comparison
included irradiation of the whole bladder over a range of
fluences from 20-60 J cm-2 for both wavelengths. On the
basis of an estimation of absorbed photon dose, however, it
seems that this comparison may not be appropriate. All but
the lowest of the 514 nm energy fluences (20 J cm-) resulted
in absorbed photon doses that were higher than that resulting
from the highest red light dose of 60 J cm-2. For example,
using the corrections for photosensitiser extinction coeffi-
cients and photon energies described above, the 30 J cm-2
green light energy fluence is equivalent to approximately
74 J cm-2 of red light at the bladder wall.
Another factor that must be considered in intracavity PDT
such as is performed in the bladder is the influence of the
integrating sphere effect and its wavelength dependence. As
discussed by Van Staveren et al. (1994) and by Star et al.
(1987), the increased diffuse intensity arising from multiple
scattering events in the wall of the cavity has the effect of
increasing the uniformity of irradiation over the surface of
the bladder and of alleviating the sensitivity to optical fibre
position. Van Staveren et al. (1994) have suggested that the
magnitude of the integrating sphere effect is appreciably
reduced at 532 nm with respect to its value at 630 nm, aud
these authors concluded that on this basis 630 nm irradiation
would be prefereable to 532 nm in whole bladder PDT.
Wavelength-dependent absorption and scattering coefficients
presented and discussed in that report indicate that
absorption decreases and scattering increases in bladder
tissue as the wavelength is lowered from 532 to 514 nm,
and it is possible that the resulting increase in the diffuse
fluence at 514 nm would be enough to provide a sufficient
integrating sphere effect. However, this is clearly an aspect of
green light dosimetry that requires more careful evaluation.
In summary, we have demonstrated a 514 nm irradiation
regimen that produces long-term tumour control in a
mesothelioma xenograft model that is statistically indistin-
guishable from that observed previously using 630 nm light.
On the basis of our experience, we suggest that for carcinoma
in situ and for lesions that are 2 mm or less in thickness, the
incident energy fluence rate at 514 nm should be approxi-
mately 20 mW cm-2 or less. For thicker lesions, stepped
irradiation protocols that increase the incident fluence rate as
therapy progresses may be optimal and should be explored
further in other tumour systems. The clinical opportunities
for using green light in Photofrinl-sensitised PDT to
optimise therapeutic ratio should be considered.
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